UHPLC Analysis of Aripiprazole and Its Primary Metabolite Dehydro Aripiprazole on Ascentis® Express C18

UHPLC Analysis of Aripiprazole and Its Primary Metabolite Dehydro Aripiprazole on Ascentis® Express C18

Conditions

column Ascentis Express C18, 10 cm x 3.0 mm, 2.0 µm particles (50819-U)
column temp. 35 °C
mobile phase [A] 10 mM ammonium formate in water, pH adjusted to 3.0 with formic acid [B] 0.1% formic acid in methanol
gradient 40% B for 0.5 min; to 95% B over 3.5 min; held at 95% B for 2 min
flow rate 0.5 mL/min
pressure 6500 psi (445 bar)
sample 50 µg/mL each compound in 10% methanol
injection 2 µL
detector UV, 245 nm

Description

Analysis Note Aripiprazole is marketed as the atypical antipsychotic Abilify for the treatment of schizophrenia, bipolar disorder, and clinical depression. Shown here is the UHPLC separation of aripiprazole and a metabolite on a Fused-Core Ascentis Express C18 column. Cerilliant CRMs provided reliable quantification.
Categories Analytical Chromatography, Antipsychotics
Featured Industry Clinical
Forensics and Toxicology
Legal Information Ascentis is a registered trademark of Sigma-Aldrich Co. LLC
suitability application for UHPLC

Materials

     
Related Links